Balkrishna Industries will hold a meeting of the Board of Directors of the Company on 2 March 2026.

Sanofi India announced that the Board of Directors of the Company at its meeting held on 25 February 2026, inter alia, have recommended the final dividend of Rs 48 per equity Share (i.e. 480%) , subject to the approval of the shareholders.

KSB announced that the Annual General Meeting(AGM) of the company will be held on 20 May 2026.

Binny will hold a meeting of the Board of Directors of the Company on 4 March 2026.

Piramal Finance today announced that CARE Ratings has upgraded its Long-Term Bank Facilities and Debentures rating to ‘CARE AA+; Stable' from ‘CARE AA; Stable', reflecting the continued strengthening of the company's financial and risk profile.

This is the second domestic rating action at the AA+ level, following CRISIL's assignment of AA+/Stable in January 2026, reinforcing confidence in Piramal Finance's business stability, earnings resilience, and overall credit strength.

Mold-Tek Technologies will hold a meeting of the Board of Directors of the Company on 28 February 2026.

Foseco India announced that the Board of Directors of the Company at its meeting held on 25 February 2026, inter alia, have recommended the final dividend of Rs 25 per equity Share (i.e. 250%) , subject to the approval of the shareholders.

John Cockerill India announced that the Board of Directors of the Company at its meeting held on 26 February 2026, has recommended a Final Dividend of Rs.7 per share (i.e.70%), subject to the approval of the shareholders.

Aurobindo Pharma announced that its wholly owned subsidiary, Eugia Pharma Specialities, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Zortress Tablets, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, of Novartis Pharmaceuticals Corp.

This approval has been received from Eugia Unit-I and is expected to be launched in Q1FY27.

The approved product has an estimated market size of US$ 78 million for the twelve months ending December 2025, according to IQVIA MAT.

This is the 184th ANDA approval (including 10 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.

Everolimus Tablets are Indicated for the prophylaxis of organ rejection in adult patients (i) Kidney Transplant: at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids (ii) Liver Transplant: Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids.

Kay Power & Paper announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 23 March 2026.